FGF2 and neoplasm: This flexible molecule is a potent inhibitor of heparanase enzymatic activity, lacks anticoagulant activity typical of heparin, and does not displace ECM-bound FGF-2 or potentiate its mitogenic activity.48,85 The modified heparin profoundly inhibits the progression of tumor xenografts produced by myeloma58,83 and Ewing’s sarcoma95 cells.